XML 22 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Cash flows used in operating activities:    
Net loss $ (1,249) $ (270)
Income from discontinued operations (65)
Depreciation and amortization 17 20
Loss on sale of interest in DSIT, net of withholding taxes and transaction costs 829
Impairment of investment in DSIT 33
Share of income in DSIT (33) (36)
Stock-based compensation 7 13
Director fees paid in common stock 4 8
Change in operating assets and liabilities:    
Decrease in accounts receivable 92 351
Decrease in inventory 27 14
Decrease in deferred charges 18 24
Decrease in other current assets and other assets 59 1
Decrease in accounts payable and accrued expenses (85) (391)
Increase in deferred revenue 34 30
Increase (decrease) in amounts due to DSIT and directors (1,271) 87
Decrease in other current liabilities and non-current liabilities (63) (143)
Net cash used in operating activities – continuing operations (1,581) (357)
Net cash used in operating activities – discontinued operations (7)
Net cash used in operating activities (1,581) (364)
Cash flows provided by (used in) investing activities:    
Proceeds from the sale of interests in DSIT, net of transaction costs 4,971
Net cash provided by investing activities 4,971
Cash flows provided by (used in) financing activities:    
Short-term credit, net 190 (102)
Proceeds from loans from directors 900
Repayment of director loans (1,300)
Repayments of loans from DSIT (340)
Net cash provided by (used in) financing activities (1,450) 798
Net increase in cash and cash equivalents 1,940 434
Cash and cash equivalents at the beginning of the year – discontinued operations 19
Cash and cash equivalents at the beginning of the year – continuing operations 481 222
Cash and cash equivalents at the end of the period – discontinued operations 12
Cash and cash equivalents at the end of the period – continuing operations 2,421 663
Non-cash investing and financing activities:    
Accrual of preferred dividends to outside investor in OmniMetrix and subsequent conversion to loan $ 25 $ 25